A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Charles Frost,1 Yan Song,1 Yu Chen Barrett,1 Jessie Wang,2 Janice Pursley,3 Rebecca A Boyd,4 Frank LaCreta1 1Exploratory Clinical and Translational Research, 2Exploratory Development Global Biometric Sciences, 3Analytical and Bioanalytical Development, Bristol-Myers Squibb Company, Princeton, NJ, U...

Full description

Bibliographic Details
Main Authors:	Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-11-01
Series:	Clinical Pharmacology : Advances and Applications
Online Access:	http://www.dovepress.com/a-randomized-direct-comparison-of-the-pharmacokinetics-and-pharmacodyn-peer-reviewed-article-CPAA

Similar Items

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
by: Frost C, et al.
Published: (2018-06-01)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
by: Frost C, et al.
Published: (2018-10-01)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
by: Upreti VV, et al.
Published: (2013-04-01)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
by: Cui Y, et al.
Published: (2013-12-01)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
by: Cui Y, et al.
Published: (2014-03-01)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
by: Frost C, et al.
Published: (2017-02-01)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Lien Thi Ngo, et al.
Published: (2020-10-01)

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Minsoo Kim, et al.
Published: (2019-03-01)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
by: Priscila B. S. Serpa, et al.
Published: (2018-12-01)

Prevention of venous thromboembolism with rivaroxaban and apixaban in orthopedic surgery
by: Antonijević Nebojša, et al.
Published: (2020-01-01)

Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01)

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
by: Tamana Meihandoest, et al.
Published: (2021-09-01)

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
by: Paul Y. Kim, et al.
Published: (2018-04-01)

A New Test for the Detection of Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in the Emergency Room Setting
by: Frydman, Galit H., et al.
Published: (2020)

Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation
by: Badreldin HA, et al.
Published: (2020-07-01)

Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation
by: Jayasree Pillarisetti, et al.
Published: (2020-11-01)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01)

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
by: Michael Becka, et al.
Published: (2012-02-01)

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study
by: Dagmar Kubitza, et al.
Published: (2018-12-01)

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for the Prevention of Stroke Prophylaxis in Atrial Fibrillation
by: Harrington, Amanda Rose
Published: (2012)

Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs
by: Noelle D. Herrera, et al.
Published: (2021-07-01)

Pharmacokinetic and pharmacodynamic
by: 蔡東湖
Published: (1995)

Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
by: L. Slavik, et al.
Published: (2019-09-01)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
by: Jia Chong, et al.
Published: (2020-01-01)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
by: Lars J Kjerpeseth, et al.
Published: (2019-01-01)

THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE
by: A. V. Kryukov, et al.
Published: (2016-06-01)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
by: Fakiha Siddiqui BDS, et al.
Published: (2019-05-01)

Effects of apixaban, rivaroxaban, dabigatran and enoxaparin on histopathology and laboratory parameters in Achilles tendon injury: An in vivo study
by: Sema Avci, et al.
Published: (2021-01-01)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
by: Ping G Tepper, et al.
Published: (2018-01-01)

Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
by: Gregory Y H Lip, et al.
Published: (2018-01-01)

A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation
by: Nathan R. Hill D.Phil, et al.
Published: (2020-01-01)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
by: Kevin Bowrin, et al.
Published: (2020-01-01)

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
by: Caroline Sindet-Pedersen, et al.
Published: (2017-06-01)

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
by: Kozue Ikeda, MD, et al.
Published: (2016-02-01)

Population pharmacokinetics and pharmacodynamics of pyronaridine
by: Methaneethorn, Janthima
Published: (2013)

Pharmacokinetic and Pharmacodynamic Studies in Anesthetics
by: Wen-YingChou, et al.
Published: (2019)

Pharmacodynamics and pharmacokinetics of snake antivenom
by: Bhagya Nikapitiya, et al.
Published: (2018-06-01)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
by: Susanna Burckhardt, et al.
Published: (2011-01-01)

Studies on the pharmacokinetics and pharmacodynamics of prazosin
by: Rubin, P. C.
Published: (1979)

Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of danofloxacin in Lohi sheep
by: Z. Manzoor, et al.
Published: (2020-12-01)